Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2016 Jun 16;127(24):2955-62.
doi: 10.1182/blood-2016-01-631200. Epub 2016 Mar 21.

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Pieter Sonneveld  1 , Hervé Avet-Loiseau  2 , Sagar Lonial  3 , Saad Usmani  4 , David Siegel  5 , Kenneth C Anderson  6 , Wee-Joo Chng  7 , Philippe Moreau  8 , Michel Attal  9 , Robert A Kyle  10 , Jo Caers  11 , Jens Hillengass  12 , Jesús San Miguel  13 , Niels W C J van de Donk  14 , Hermann Einsele  15 , Joan Bladé  16 , Brian G M Durie  17 , Hartmut Goldschmidt  18 , María-Victoria Mateos  19 , Antonio Palumbo  20 , Robert Orlowski  21
Affiliations
Practice Guideline

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Pieter Sonneveld et al. Blood. .

Abstract

The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The prognosis of patients showing these abnormalities may vary with the choice of therapy. Treatment strategies have shown promise for HR cytogenetic diseases, such as proteasome inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immunotherapy with lenalidomide or pomalidomide. Careful analysis of cytogenetic subgroups in trials comparing different treatments remains an important goal. Cross-trial comparisons may provide insight into the effect of new drugs in patients with cytogenetic abnormalities. However, to achieve this, consensus on definitions of analytical techniques, proportion of abnormal cells, and treatment regimens is needed. Based on data available today, bortezomib and carfilzomib treatment appear to improve complete response, progression-free survival, and overall survival in t(4;14) and del(17/17p), whereas lenalidomide may be associated with improved progression-free survival in t(4;14) and del(17/17p). Patients with multiple adverse cytogenetic abnormalities do not benefit from these agents. FISH data are implemented in the revised International Staging System for risk stratification.

PubMed Disclaimer

References

    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060. - PubMed
    1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. - PubMed
    1. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335–348. - PubMed
    1. Hervé AL, Florence M, Philippe M, et al. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol. 2011;29(14):1893–1897. - PubMed
    1. Usmani SZ, Crowley J, Hoering A, et al. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia. 2013;27(1):226–232. - PMC - PubMed

Publication types